Corrigendum to “Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives” [Crit. Rev. Oncol./Hematol. 181 (2023) 103900]

IF 5.5 2区医学 Q1 HEMATOLOGY Critical reviews in oncology/hematology Pub Date : 2024-06-13 DOI:10.1016/j.critrevonc.2024.104308

Marianna Sirico , Alessandra Virga , Benedetta Conte , Milena Urbini , Paola Ulivi , Caterina Gianni , Filippo Merloni , Michela Palleschi , Marco Gasperoni , Annalisa Curcio , Debjani Saha , Giuseppe Buono , Montserrat Muñoz , Ugo De Giorgi , Francesco Schettini

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

腔隙性乳腺肿瘤的新辅助内分泌治疗：181 (2023) 103900]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.